Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic features of renal cell carcinoma with venous tumor thrombus.
Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S. Warsow G, et al. Among authors: nientiedt c. Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z. Sci Rep. 2018. PMID: 29748622 Free PMC article.
PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. Ann Oncol. 2017. PMID: 27687312 Free article. No abstract available.
Mutations in BRCA2 and taxane resistance in prostate cancer.
Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x. Sci Rep. 2017. PMID: 28676659 Free PMC article.
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S. Chen X, et al. Among authors: nientiedt c. Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1. Urol Oncol. 2018. PMID: 29198908
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.
Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Apostolidis L, et al. Among authors: nientiedt c. Oncotarget. 2019 Jan 1;10(1):17-29. doi: 10.18632/oncotarget.26523. eCollection 2019 Jan 1. Oncotarget. 2019. PMID: 30713600 Free PMC article.
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. Jenzer M, et al. Among authors: nientiedt c. Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23. Cancer Immunol Immunother. 2019. PMID: 31549213 Free PMC article.
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.
Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A. Kratochwil C, et al. Among authors: nientiedt c. J Nucl Med. 2020 May;61(5):683-688. doi: 10.2967/jnumed.119.234559. Epub 2019 Oct 10. J Nucl Med. 2020. PMID: 31601699 Free article.
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
Nientiedt C, Endris V, Jenzer M, Mansour J, Sedehi NTP, Pecqueux C, Volckmar AL, Leichsenring J, Neumann O, Kirchner M, Hoveida S, Lantwin P, Kaltenecker K, Dieffenbacher S, Gasch C, Hofer L, Franke D, Tosev G, Görtz M, Schütz V, Radtke JP, Nyarangi-Dix J, Hatiboglu G, Simpfendörfer T, Schönberg G, Isaac S, Teber D, Koerber SA, Christofi G, Czink E, Kreuter R, Apostolidis L, Kratochwil C, Giesel F, Haberkorn U, Debus J, Sültmann H, Zschäbitz S, Jäger D, Duensing A, Schirmacher P, Grüllich C, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Urol Oncol. 2020 Jul;38(7):637.e17-637.e27. doi: 10.1016/j.urolonc.2020.03.001. Epub 2020 Apr 10. Urol Oncol. 2020. PMID: 32280037 Free article.
Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53.
Kaczorowski A, Tolstov Y, Falkenstein M, Vasioukhin V, Prigge ES, Geisler C, Kippenberger M, Nientiedt C, Ratz L, Kuryshev V, Herpel E, Kristiansen G, Sültmann H, Stenzinger A, Doeberitz MVK, Hohenfellner M, Duensing A, Duensing S. Kaczorowski A, et al. Among authors: nientiedt c. Urol Oncol. 2020 Sep;38(9):736.e1-736.e10. doi: 10.1016/j.urolonc.2020.06.016. Epub 2020 Jul 13. Urol Oncol. 2020. PMID: 32674955 Free article.
PARP inhibition in prostate cancer.
Nientiedt C, Duensing A, Zschäbitz S, Jäger D, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Genes Chromosomes Cancer. 2021 May;60(5):344-351. doi: 10.1002/gcc.22903. Epub 2020 Oct 28. Genes Chromosomes Cancer. 2021. PMID: 33084183 Review.
16 results